Abstract

Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family (PGC-1s), consisting of three members encompassing PGC-1α, PGC-1β, and PGC-1-related coactivator (PRC), was discovered more than a quarter-century ago. PGC-1s are essential coordinators of many vital cellular events, including mitochondrial functions, oxidative stress, endoplasmic reticulum homeostasis, and inflammation. Accumulating evidence has shown that PGC-1s are implicated in many diseases, such as cancers, cardiac diseases and cardiovascular diseases, neurological disorders, kidney diseases, motor system diseases, and metabolic disorders. Examining the upstream modulators and co-activated partners of PGC-1s and identifying critical biological events modulated by downstream effectors of PGC-1s contribute to the presentation of the elaborate network of PGC-1s. Furthermore, discussing the correlation between PGC-1s and diseases as well as summarizing the therapy targeting PGC-1s helps make individualized and precise intervention methods. In this review, we summarize basic knowledge regarding the PGC-1s family as well as the molecular regulatory network, discuss the physio-pathological roles of PGC-1s in human diseases, review the application of PGC-1s, including the diagnostic and prognostic value of PGC-1s and several therapies in pre-clinical studies, and suggest several directions for future investigations. This review presents the immense potential of targeting PGC-1s in the treatment of diseases and hopefully facilitates the promotion of PGC-1s as new therapeutic targets.

Details

Title
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases
Author
Qian, Lu 1 ; Zhu, Yanli 1 ; Deng, Chao 2 ; Liang, Zhenxing 3 ; Chen, Junmin 1 ; Chen, Ying 4 ; Wang, Xue 2 ; Liu, Yanqing 1 ; Tian, Ye 1 ; Yang, Yang 1   VIAFID ORCID Logo 

 The Affiliated Hospital of Northwest University, Northwest University, Xi’an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi’an No.3 Hospital, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538); Northwest University, Xi’an Key Laboratory of Innovative Drug Research for Heart Failure, Faculty of Life Sciences and Medicine, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538) 
 The First Affiliated Hospital of Xi’an Jiaotong University, Department of Cardiovascular Surgery, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119) 
 The First Affiliated Hospital of Zhengzhou University, Department of Cardiothoracic Surgery, Zhengzhou, China (GRID:grid.412633.1) 
 The First Affiliated Hospital of Xi’an Jiaotong University, Department of Hematology, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119) 
Pages
50
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2933288535
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.